These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 20707760)

  • 41. Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
    Alborghetti M; Nicoletti F
    Curr Neuropharmacol; 2019; 17(9):861-873. PubMed ID: 30160213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The safety and efficacy of safinamide mesylate for the treatment of Parkinson's disease.
    Perez-Lloret S; Rascol O
    Expert Rev Neurother; 2016; 16(3):245-58. PubMed ID: 26849427
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of early Parkinson's disease. Part 1.
    Simuni T; Lyons KE; Pahwa R; Hauser RA; Comella C; Elmer L; Weintraub D
    Eur Neurol; 2009; 61(4):193-205. PubMed ID: 19176960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of dopamine receptor agonists in the treatment of early Parkinson's disease.
    Bonuccelli U; Del Dotto P; Rascol O
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S44-53. PubMed ID: 20123557
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
    Henchcliffe C; Schumacher HC; Burgut FT
    Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
    Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
    J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study.
    Bianchini E; Sforza M; Rinaldi D; Alborghetti M; De Carolis L; Della Gatta F; Pontieri FE
    Neurol Res; 2021 Nov; 43(11):950-954. PubMed ID: 34142645
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Future therapies for Parkinson's disease.
    Hauser RA; Lyons KE
    Neurol Clin; 2004 Oct; 22(3 Suppl):S149-66. PubMed ID: 15501363
    [No Abstract]   [Full Text] [Related]  

  • 51. Safinamide as an adjunct therapy in older patients with Parkinson's disease: a retrospective study.
    Lo Monaco MR; Petracca M; Vetrano DL; Di Stasio E; Fusco D; Ricciardi D; Laudisio A; Zuccalà G; Onder G; Bentivoglio AR
    Aging Clin Exp Res; 2020 Jul; 32(7):1369-1373. PubMed ID: 31981101
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comment on: Safinamide as adjunctive therapy for Parkinson's disease: A promising option with room for improvement.
    Matovu D
    J Neurol Sci; 2024 Jul; 462():123103. PubMed ID: 38925997
    [No Abstract]   [Full Text] [Related]  

  • 53. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New pharmacologic strategies for the treatment of Parkinson disease].
    Tolosa E; Molinuevo JL; Valldeoriola F; Pastor P
    Neurologia; 1999 May; 14 Suppl 1():46-53. PubMed ID: 10377729
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study.
    Liguori C; Stefani A; Ruffini R; Mercuri NB; Pierantozzi M
    Parkinsonism Relat Disord; 2018 Dec; 57():80-81. PubMed ID: 30006034
    [No Abstract]   [Full Text] [Related]  

  • 56. Safinamide in neurological disorders and beyond: Evidence from preclinical and clinical studies.
    Wasan H; Singh D; Kh R
    Brain Res Bull; 2021 Mar; 168():165-177. PubMed ID: 33387637
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advances in the pharmacologic management of early Parkinson disease.
    Hauser RA; Zesiewicz TA
    Neurologist; 2007 May; 13(3):126-32. PubMed ID: 17495756
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition.
    Stocchi F; Vacca L; Grassini P; De Pandis MF; Battaglia G; Cattaneo C; Fariello RG
    Neurology; 2006 Oct; 67(7 Suppl 2):S24-9. PubMed ID: 17030737
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An expert opinion on safinamide in Parkinson's disease.
    Onofrj M; Bonanni L; Thomas A
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
    Piccoli F; Riuggeri RM
    J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.